Stem Cell Therapy - Blue Horizon Stem Cells By: Michael McDermott … Continue reading →

Tokyo, Apr 10, 2013 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has presented preclinical research findings suggesting a potential inhibitory effect on tumor metastasis as a possible novel mechanism of action for anticancer agent Halaven(R) (eribulin mesylate, "eribulin") at the American Association for Cancer Research (AACR) 104th Annual Meeting ("AACR 2013"). Among the research findings presented by Eisai at AACR 2013 were gene expression profiling (GEP) analyses of multiple cancer cell lines, which confirmed that eribulin altered expression in epithelial-mesenchymal transition (EMT) gene sets. EMT was first recognized in the early 1980s and was long assumed to be a feature of embryogenesis in which embryonic epithelial cells acquire mesenchymal characteristics that lead to cell migration1; however, EMT has in recent years also been reported 2 to perform a role in numerous disease states in adult stages and, particularly in the acquisition of EMT phenotypes in epithelial cancer cells, to be highly relevant to the infiltration and metastasis of cancer. Eisai also presented a dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) analysis of human breast xenograft tumors in rats, which confirmed that eribulin improved blood perfusion in the core of tumor tissues ("tumor core"). These findings indicated that … Continue reading →

A horse is given an injection of stem cells in a bid to promote healing in a tendon injury. Lauren Schnabel/Jessica Cross/Cornell Univ. Patients seeking unproven stem-cell therapies in the United States often run up against government restrictions. But Vintage Vinty Mark of Lovettsville, Virginia, had no difficulty getting such injections to treat an injured tendon in his leg. The leg improved dramatically, and Vinty went back to training to be a racehorse. New guidance from the US Food and Drug Administration (FDA) could, however, soon rein in veterinary uses of stem cells, a practice that has exploded in the United States over the past decade, even though most therapies are unproven. Many researchers and veterinarians say that the guidance, a draft of which the agency plans to issue by the end of the year, is overdue. But others worry that FDA interference could hamper research that could benefit animals and their human companions. In the absence of clear regulations, the industry has burgeoned. Vet-Stem, a company based in Poway, California, has provided stem-cell treatments to more than 5,000 horses, 4,300 dogs and 120 cats since treating its first patient in 2004. Kits provided by MediVet America, based in Nicholasville, … Continue reading →